Improved therapeutic approach for spinal muscular atrophy via ubiquitination‐resistant survival motor neuron variant
Journal of Cachexia, Sarcopenia and Muscle · 2024
DOI: 10.1002/jcsm.13486 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cachexia, Sarcopenia and Muscle, 2024. Verfasst von Joonwoo Rhee und 9 weiteren Autor:innen. Beteiligte Einrichtung: School of Biological Sciences, Seoul National University, Seoul, South Korea. Hauptthemen laut MEDLINE: Muscular Atrophy, Spinal, Disease Models, Animal, Genetic Therapy, Ubiquitination. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Foundation of Korea, Korea Mouse Phenotyping Project of the Ministry of Science and ICT, Ministry of Education.
Abstract (Originalsprache)
Background
Zolgensma is a gene‐replacement therapy that has led to a promising treatment for spinal muscular atrophy (SMA). However, clinical trials of Zolgensma have raised two major concerns: insufficient therapeutic effects and adverse events. In a recent clinical trial, 30% of patients failed to achieve motor milestones despite pre‐symptomatic treatment. In addition, more than 20% of patients showed hepatotoxicity due to excessive virus dosage, even after the administration of an immunosuppressant. Here, we aimed to test whether a ubiquitination‐resistant variant of survival motor neuron (SMN), SMN K186R , has improved therapeutic effects for SMA compared with wild‐type SMN (SMN WT ).
Methods
A severe SMA mouse model, SMA type 1.5 ( Smn −/− ; SMN2 +/+ ; SMN∆7 +/− ) mice, was used to compare the differences in therapeutic efficacy between AAV9‐SMN WT and AAV9‐SMN K186R . All animals were injected within Postnatal Day (P) 1 through a facial vein or cerebral ventricle.
Results
AAV9‐SMN K186R ‐treated mice showed increased lifespan, body weight, motor neuron number, muscle weight and functional improvement in motor functions as compared with AAV9‐SMN WT ‐treated mice. Lifespan increased by more than 10‐fold in AAV9‐SMN K186R ‐treated mice (144.8 ± 26.11 days) as compared with AAV9‐SMN WT ‐treated mice (26.8 ± 1.41 days). AAV9‐SMN K186R ‐treated mice showed an ascending weight pattern, unlike AAV9‐SMN WT ‐treated mice, which only gained weight until P20 up to 5 g on average. Several motor function tests showed the improved therapeutic efficacy of SMN K186R . In the negative geotaxis test, AAV9‐SMN K186R ‐treated mice turned their bodies in an upward direction successfully, unlike AAV9‐SMN WT ‐treated mice, which failed to turn upwards from around P23. Hind limb clasping phenotype was rarely observed in AAV9‐SMN K186R ‐treated mice, unlike AAV9‐SMN WT ‐treated mice that showed clasping phenotype for more than 20 out of 30 s. At this point, the number of motor neurons (1.5‐fold) and the size of myofibers (2.1‐fold) were significantly increased in AAV9‐SMN K186R ‐treated mice compared with AAV9‐SMN WT ‐treated mice without prominent neurotoxicity. AAV9‐SMN K186R had fewer liver defects compared with AAV9‐SMN WT , as judged by increased proliferation of hepatocytes ( P < 0.0001) and insulin‐like growth factor‐1 production ( P < 0.0001). Especially, low‐dose AAV9‐SMN K186R (nine‐fold) also reduced clasping time compared with SMN WT .
Conclusions
SMN K186R will provide improved therapeutic efficacy in patients with severe SMA with insufficient therapeutic efficacy. Low‐dose treatment of SMA patients with AAV9‐SMN K186R can reduce the adverse events of Zolgensma. Collectively, SMN K186R has value as a new treatment for SMA that improves treatment effectiveness and reduces adverse events simultaneously.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Biological Sciences, Seoul National University, Seoul, South Korea.
- Molecular Recognition Research Center, Korea Institute of Science and Technology, Seoul, South Korea.
ORCID-Profile: Young-Yun Kong
Förderung
- National Research Foundation of Korea
- Korea Mouse Phenotyping Project of the Ministry of Science and ICT
- Ministry of Education
- Korea Institute of Science and Technology (KIST) Institutional Program
Zitieren
APA
Rhee, J., Kang, J. S., Jo, Y. W., Yoo, K., Kim, Y. L., Hann, S. H., Kim, Y. E., Kim, H., Kim, J. H., & Kong, Y. Y. (2024). Improved therapeutic approach for spinal muscular atrophy via ubiquitination‐resistant survival motor neuron variant. Journal of Cachexia, Sarcopenia and Muscle. https://doi.org/10.1002/jcsm.13486
Vancouver
Rhee J, Kang JS, Jo YW, Yoo K, Kim YL, Hann SH, et al. Improved therapeutic approach for spinal muscular atrophy via ubiquitination‐resistant survival motor neuron variant. Journal of Cachexia, Sarcopenia and Muscle. 2024. doi:10.1002/jcsm.13486
BibTeX
@article{Rhee2024,
author = {Rhee, Joonwoo and Kang, Jong-Seol and Jo, Young-Woo and Yoo, Kyusang and Kim, Ye Lynne and Hann, Sang-Hyeon and Kim, Yea-Eun and Kim, Hyun and Kim, Ji-Hoon and Kong, Young-Yun},
title = {Improved therapeutic approach for spinal muscular atrophy via ubiquitination‐resistant survival motor neuron variant},
journal = {Journal of Cachexia, Sarcopenia and Muscle},
year = {2024},
doi = {10.1002/jcsm.13486}
}
EUVIMED